C-reactive protein, left ventricular mass index and risk of cardiovascular disease in essential hypertension

Hypertension Research

Volumn 30, Issue 12, 2007, Pages 1177-1185

  Iwashima, Yoshio ^a   Horio, Takeshi ^b   Kamide, Kei ^b   Rakugi, Hiromi ^a   Ogihara, Toshio ^a   Kawano, Yuhei ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

C reactive protein; Cardiovascular disease; Echocardiography; Follow up study; Hypertrophy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 38749135523     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.1177     Document Type: Article

References (40)

1. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Verma S, Wang CH, Li SH, et al: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
3. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM: C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
4. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-1441.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
6. Koenig W, Sund M, Frohlich M, et al: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
7. Danesh J, Whincup P, Walker M, et al: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
8. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-2485.
9. Rost NS, Wolf PA, Kase CS, et al: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32: 2575-2579.
10. Tracy RP, Lemaitre RN, Psaty BM, et al: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-1127.
11. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
12. Pearson TA, Mensah GA, Alexander RW, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health-care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
13. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
14. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
15. Kim BS, Jeon DS, Shin MJ, et al: Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol 2005; 25: 189-195.
16. Olsen MH, Christensen MK, Hansen TW, et al: High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. J Hypertens 2006; 24: 655-661.
17. Conen D, Zeller A, Pfisterer M, Martina B: Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 2006; 97: 249-252.
18. Palmieri V, Tracy RP, Roman MJ, et al: Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care 2003; 26: 2764-2769.
19. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A: Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 2116-2123.
20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26 (Suppl 1): S5-S20.
21. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y: Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195-202.
22. Iwashima Y, Horio T, Takami Y, et al: Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40: 974-982.
23. Schiller NB, Shah PM, Crawford M, et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
24. Cooper JW, Nanda NC, Philpot EF, Fan P: Evaluation of valvular regurgitation by color Doppler. J Am Soc Echocardiogr 1989; 2: 56-66.
25. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
26. Basnight MA, Gonzalez MS, Kershenovich SC, Appleton CP: Pulmonary venous flow velocity: relation to hemodynamics, mitral flow velocity and left atrial volume, and ejection fraction. J Am Soc Echocardiogr 1991; 4: 547-558.
27. McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-1446.
28. Mosterd A, Deckers JW, Hoes AW, et al: Classification of heart failure in population based research: an assessment of six heart failure scores. Eur J Epidemiol 1997; 13: 491-502.
29. Hammond IW, Devereux RB, Alderman MH, et al: The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7: 639-650.
30. Saijo Y, Yoshioka E, Fukui T, Kawaharada M, Kishi R: Metabolic syndrome, C-reactive protein and increased arterial stiffness in Japanese subjects. Hypertens Res 2006; 29: 589-596.
31. Frohlich M, Imhof A, Berg G, et al: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-1839.
32. Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 1971-1977.
33. Blake GJ, Rifai N, Buring JE, Ridker PM: Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999.
34. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
35. Zhong W, Zen Q, Tebo J, Schlottmann K, Coggeshall M, Mortensen RF: Effect of human C-reactive protein on chemokine and chemotactic factor-induced neutrophil chemotaxis and signaling. J Immunol 1998; 161: 2533-2540.
36. Mazer SP, Rabbani LE: Evidence for C-reactive protein's role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP. J Thromb Thrombolysis 2004; 17: 95-105.
37. Bisoendial RJ, Kastelein JJ, Levels JH, et al: Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-716.
38. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.
39. Lowe GD, Sweetnam PM, Yarnell JW, et al: C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004; 24: 1957-1962.
40. Schillaci G, Pasqualini L, Verdecchia P, et al: Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002; 39: 2005-2011.